Home/Passage Bio/William Chou
WC

William Chou

Chief Executive Officer

Passage Bio

Therapeutic Areas

Passage Bio Pipeline

DrugIndicationPhase
PBFT02Frontotemporal Dementia with progranulin mutations (FTD-GRN)Phase 1/2
PBGM01Infantile GM1 GangliosidosisPhase 1/2